Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (13)

2022

  1. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer

    International Journal of Gynecological Cancer, Vol. 32, Núm. 8, pp. 1009-1016

2021

  1. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

2014

  1. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

    British journal of cancer, Vol. 111, Núm. 6, pp. 1060-1064

  2. Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I-trial

    Molecular Oncology, Vol. 8, Núm. 8, pp. 1719-1728

2013

  1. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC

    International Journal of Cancer, Vol. 132, Núm. 9, pp. 1986-1995

2009

  1. A gene-alteration profile of human lung cancer cell lines

    Human Mutation, Vol. 30, Núm. 8, pp. 1199-1206

2008

  1. Frequent BRG1/SMARCA4-Inactivating mutations in human lung cancer cell lines

    Human Mutation, Vol. 29, Núm. 5, pp. 617-622

2007

  1. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway

    Neoplasia, Vol. 9, Núm. 10, pp. 840-852

2004

  1. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene

    Oncogene, Vol. 23, Núm. 22, pp. 4037-4040